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Gut bacterial tyrosine decarboxylase associates with clinical
variables in a longitudinal cohort study of Parkinsons disease
Sebastiaan P. van Kessel 1, Petri Auvinen 2, Filip Scheperjans 3,4✉ and Sahar El Aidy 1,4✉
Gut microbiota influences the clinical response of a wide variety of orally administered drugs. However, the underlying mechanisms
through which drug–microbiota interactions occur are still obscure. Previously, we reported that tyrosine decarboxylating (TDC)
bacteria may restrict the levels of levodopa reaching circulation in patients with Parkinson’s disease (PD). We observed a significant
positive association between disease duration and the abundance of the bacterial tdc-gene. The question arises whether increased
exposure to anti-PD medication could affect the abundance of bacterial TDC, to ultimately impact drug efficacy. To this end, we
investigated the potential association between anti-PD drug exposure and bacterial tdc-gene abundance over a period of 2 years in
a longitudinal cohort of PD patients and healthy controls. Our data reveal significant associations between tdc-gene abundance,
several anti-PD medications, including entacapone, rasagiline, pramipexole, and ropinirole but not levodopa, and gastrointestinal
symptoms, warranting further research on the effect of anti-PD medication on microbial changes and gastrointestinal function.
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INTRODUCTION
In recent years, many studies have focused on the changes in
microbiota composition in individuals with Parkinson’s disease
(PD) compared to healthy subjects (extensively covered in several
systematic reviews1,2 among others). While certain differential
abundance alterations were reproduced across studies, variation
of results remained considerable1,2. One of the reasons that may
explain the inconsistency among these studies are confounding
factors, such as anti-PD medications, disease duration, and
gastrointestinal (GI) symptoms. Indeed, studies took these factors
into account with variable effort. Catechol-O-methyltransferase
(COMT) inhibitors, anticholinergics, and potentially levodopa/
carbidopa were found to have a significant effect on the changes
in the microbiota3–6. Apart from medication, GI dysfunction should
be considered when analyzing the altered microbiota in PD
patients. Indeed, PD patients usually experience more GI
dysfunction symptoms compared to healthy controls (HCs)7,8
and intestinal transit time can impact microbiota composition9.
Moreover, it has been shown that there is an association
between anti-PD medication and GI symptoms. For example, anti-
PD medications have been associated (corrected for disease
duration) with the total GI Symptoms Rating Score, upper GI
symptoms, and hypoactive GI functions8. Furthermore, COMT
inhibitor dosage was significantly higher in patients with an
abnormal transit time compared to those with normal transit
time10. However, the statistical analysis in that study could not
distinguish whether levodopa equivalent daily dose (LEDD) or
disease duration was the larger contributing factor to slow colon
transit10. In addition, ex vivo rodent studies and in vivo dog and
human studies showed an effect of dopamine agonists and/or
dopamine (which can originate from levodopa in PD patients) on
gut motility, as recently reviewed11 (and citations therein). Gut
microbial metabolization of unabsorbed residues of levodopa
were also shown to influence ileal motility ex vivo12.
Recent studies have shown that tyrosine decarboxylating (TDC)
bacteria can decarboxylate levodopa into dopamine in the
periphery, thus restricting levodopa availability to the brain13,14.
Potentially, TDC-harboring bacteria could create a vicious circle,
wherein peripheral dopamine production affects gut motility,
favoring the colonization of (TDC)-bacteria13. Additionally, non-
levodopa anti-PD medications (monoaminoxidase inhibitors,
COMT inhibitors, and dopamine agonists), which affect the
peripheral dopaminergic balance, may lead to an altered GI
function, potentially contributing to (TDC)-bacterial overgrowth
and ultimately variable bioavailability of levodopa. However, levels
of TDC-bacteria have not yet been measured nor previously
correlated with GI symptoms in longitudinal PD cohorts.
In this study, we focused on measuring fecal tdc-gene
abundance and its association with anti-PD medication exposure
in a 2-year longitudinal cohort consisting of 67 PD patients and 65




Clinical variable comparison between the longitudinal cohort of
PD and HCs did not reveal any significant differences in sex, age
(at stool collection), or body mass index, with no systemic
antibiotics used by either group within the last month
(Supplementary Table 1). The duration of motor and non-motor
symptom onset in the PD cohort at baseline was ~8 years
(Supplementary Table 1). Over time (between baseline and
follow-up), the LEDD significantly increased by an average of
116 mg (Table 1). On average, the Unified Parkinson’s Disease
Rating Scale (UPDRS) I and II scores significantly increased over
time, while UPDRS III (at ON state) significantly decreased
(Supplementary Table 2). The latter may be explained by the
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significant LEDD increase over time. The Hoehn & Yahr (at ON
state) score slightly increased over time (Supplementary Table 2).
Gut bacterial tdc-gene abundance, GI symptoms, and
medication exposure significantly increased over time in PD
patients
It has recently been shown that TDC-bacteria in the GI tract
interferes with the availability of levodopa medication in animal
models and that longer disease duration and exposure to
levodopa may further increase the abundance of TDC-bacteria in
the gut13. Thus, we sought to investigate the changes in the levels
of gut bacterial tdc-gene abundance over time in a longitudinal
PD cohort, including the differences between PD patients and
matching HCs.
High prevalence of the tdc-gene was detected at baseline in
97% (n= 61/63) and 98% (n= 61/62) of the HC and PD samples,
respectively. Likewise, at follow-up the tdc-gene was detected in
100% (n= 64/64) and 98% (n= 63/64) of the HC and PD samples,
respectively. When comparing PD patients and HCs, PD patients
tended to have a higher tdc-gene abundance (p= 0.057) at follow-
up (Fig. 1 and Table 2). Correspondingly, the increase in tdc-gene
abundance over time was significantly higher in PD patients
compared to HC subjects (Wilcoxon test, p= 9.7E−07), with a
mean increase of 2.6-fold (Table 1 and Fig. 1). The results indicate
that, over time, tdc-gene abundance increases more rapidly in PD
patients compared to HC subjects.
Because GI transit time also impacts microbial composition
(including TDC bacteria)9, differences in GI symptoms were
assessed at baseline and follow-up. At both time points, GI
symptoms were significantly more severe in PD patients















































































































































































































































































































































































































































































Fig. 1 tdc-gene abundance in PD and healthy control subjects.
The tdc-gene abundance is depicted for PD patients (PD, red boxes;
dark, baseline; light, follow-up) and healthy control subjects (HCs,
gray boxes; dark, baseline; light, follow-up) for both time points.
Nonparametric paired Wilcoxon tests (W) were performed to test for
significant increase over time between paired samples (gray lines).
Significant outliers were removed using the ROUT method (Q=
0.1%). Nonparametric unpaired Mann–Whitney tests (M-W) were
performed to test for significant differences between PD and HCs at
baseline and follow-up. Boxes represent the median with the
interquartile range and whiskers the maxima and minima.
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not the Rome III scores, increased significantly over time in PD
patients, while in HC subjects the Wexner scores decreased
significantly over time (Table 1).
Although the LEDD increased significantly over time (Table 1),
no significant increase was observed for any individual drug in
PD patients after correction for FDR, possibly due to changes in
medication type (Table 1). When medication shared between
the PD and HC groups was compared at baseline, anticholinergic
medication use was significantly higher in PD patients compared
to HC subjects (Table 2). In the HC group only, a significant
decrease in antacids medication use was observed over time
(Table 1).
Anti-PD medication and GI symptoms associate with the gut
bacterial tdc-gene abundance over time
Using general linear models (GLMs), the contribution of the
difference in anti-PD medication exposure to the difference in
tdc-gene abundance over time (follow-up–baseline) was
assessed (Table 3). The model showed that dose changes of
entacapone, rasagiline, pramipexole, and ropinirole significantly
contributed to differenential tdc-gene abundance over time.
Entacapone and the dopamine agonists contributed positively to
the difference in tdc-gene abundance, while monoamine oxidase
inhibitor (MAOi) contributed negatively to the tdc-gene abun-
dance over time, respectively.
Because the Wexner scores, but not Rome III, significantly
increased over time in the PD group (Table 1), this factor was
included in the model to correct for its potential contribution to
the tdc-gene abundance. Remarkably, Wexner total scores
significantly contributed negatively to the tdc-gene abundance
(Table 3), suggesting that subjects with less constipation have an
increased tdc-gene abundance. Correction for Wexner scores
showed that the difference in exposure to anti-PD medication,
stated above, still contributed to the model except for ropinirole
(p= 0.107). The results indicate that prolonged exposure of these
specific anti-PD medications, excluding levodopa, contributed to
tdc-gene abundance independent of the changes in GI symptoms
measured by Wexner scores.
PD patients usually require alterations in their anti-PD dosage
regimen during disease progression, compared to patients in a
steady state of the disease. Thus, we sought to investigate whether
differences in anti-PD dosing between the two groups were a
contributing factor to the changes in tdc-gene abundance observed
above (Table 3). To this end, the PD group was subdivided into slow
progressing (n= 35) and rapid progressing (n= 12) PD patients
using the third quartile of the sum of the z-transformed changes in
UPDRS I-III score (in the ON state) and LEDD between baseline and
follow-up as cut-off, as described and performed in Aho et al.4.
Comparing the mean differences of medications taken by slow and
rapid progressing PD patients over time showed that exposure to
levodopa and entacapone significantly increased, while pramipexole
exposure significantly decreased in the rapid compared to the slow
progressing group (Table 4).
When comparing the slow progressing PD patient group with
the rapid progressing PD patient group (Table 5), only entacapone
was not associated with tdc-gene abundance, and rotigotine now
significantly contributed to the model (which was not observed in
all PD patients, Table 3). However, the significance was lost when
correcting for Wexner score.
In the rapid progressing PD group, only entacapone contributed
significantly to the change in tdc-abundance (Table 5). Because
the variation inflation factor (VIF, which tests if the variance of a
variable increases with another) suggested collinearity between
factors in the rapid progressing PD group, DA agonists and MAOi
were combined using LEDD calculation15. Using the combined
variables in the GLM, no collinearity was observed any longer,
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abundance (Supplementary Table 3). These results indicate that
the difference in drug exposure over time between slow and rapid
progressing PD patients (Table 4) reflect their contribution to the
tdc-gene abundance in the GLMs (Table 5 and Supplementary
Table 3). In summary, these observations indicate that the change
in exposure to specific anti-PD medications, like entacapone, can
be a significant contributing factor to an increase in tdc-gene
abundance in rapid progressing PD patients. Concomitantly, other
anti-PD medications contribute to tdc-gene abundance in slow
progressing PD patients.
DISCUSSION
In this study, we have established that gut bacterial tdc-gene
abundance significantly increases over time in PD patients
(Table 1), in line with previous results, where a significant
correlation between disease duration and tdc-gene abundance
was observed13. The levels of gut bacterial tdc-gene abundance
were not significantly different compared to HCs at baseline but
close to significant at follow-up (Table 2). Accordingly, the increase
in tdc-gene abundance was 2.6-fold higher in PD than in HCs,
suggesting that the increased gene abundance occurs more
rapidly in PD patients. Here, we did not find a significant
correlation between levodopa dosage and tdc-gene abundance.
This discrepancy could be explained by the relatively low
proportion of high levodopa dosages in this study. At baseline
and follow-up, 19.4% (max 900mg) and 26.9% (max 875 mg) of
the PD patients had a dose higher than 400 mg/day, respectively,
while in the previous study13 60% of the PD patients received a
dosage higher than 400mg/day (max 1100mg).
Using GLMs, we showed that several anti-PD medications other
than levodopa contributed significantly to the tdc-gene abun-
dance. Importantly, all tested medications (Table 3) affect the
(peripheral) dopaminergic system; COMT inhibitors prevent
methylation of levodopa, dopamine, and norepinephrine; MAOis
prevent dopamine and norepinephrine oxidation; and DA agonists
act on dopamine receptors expressed in the gut. Collectively,
these medications were recently shown to elicit an effect on GI
symptoms8. Although GI dysfunction might be caused by the
degeneration of enteric neurons, as observed in PD patients with
chronic constipation16 and reported in an MPTP mouse model for
PD17, additional dopaminergic medication may impact the GI
function even further. Indeed, the Wexner score, which signifi-
cantly increased over time in PD patients, did not change the
associations between anti-PD medication and tdc-gene abun-
dance (except for ropinirole exposure) when considered as a
confounder. The potential link between changes in GI symptoms,
as measured by Wexner score, and anti PD medications are in
Table 3. General linear model of the difference tdc-gene abundance overtime with anti-PD medication and Wexner score as variables (significant
variable contributions to the model are printed in bold).
All PD patients (n= 55) Difference tdc-gene abundance 2y–0y (no outliers)
Not corrected for Wexner score Corrected for Wexner score
β p value VIF β p value VIF
(Intercept) 2.1E−06 0.000 2.5E−06 0.000
Difference levodopa sum (mg) 1.0E−09 0.671 1.375 −3.2E−10 0.895 1.466
Difference entacapone (mg) 2.1E−09 0.032 1.163 2.4E−09 0.011 1.189
Difference selegeline (mg) −9.4E−08 0.258 1.215 −1.0E−07 0.191 1.218
Difference rasagiline (mg) −2.7E−06 0.035 1.366 −3.0E−06 0.013 1.388
Difference rotigotine (mg) 2.3E−07 0.245 1.161 1.7E−07 0.374 1.184
Difference pramipexole (mg) 2.0E−06 0.001 1.415 1.7E−06 0.005 1.515
Difference ropinirole (mg) 2.2E−07 0.028 1.367 1.6E−07 0.107 1.472
Difference in Wexner total score Not included −3.0E−07 0.024 1.265
VIF variance inflation factor.
Table 4. Independent tests between slow and rapid progressing PD patients of exposure of anti-PD medications over time (significant test results
are printed in bold).




mean ± SD (n)
Slow progressing
mean ± SD (n)
T test Mann–Whitney Fishers’s test FDR
Difference levodopa
sum (mg)
103.5 208.33 ± 156.43 (12) 104.86 ± 116.32 (36) 0.022 0.051
Difference entacapone (mg) 361.1 366.67 ± 510.50 (12) 5.56 ± 255.17 (36) 0.009 0.051
Difference selegeline (mg) 1.5 0.83 ± 5.15 (12) −0.68 ± 4.46 (36) 0.737 0.983
Difference rasagiline (mg) 0.0 0.08 ± 0.29 (12) 0.08 ± 0.28 (36) 0.934 0.983
Difference rotigotine (mg) 0.4 0.83 ± 2.89 (12) 0.39 ± 1.34 (36) 0.983 0.983
Difference pramipexole (mg) −0.4 −0.31 ± 0.65 (12) 0.10 ± 0.58 (36) 0.019 0.051
Difference ropinirole (mg) −0.3 −0.58 ± 5.53 (12) −0.28 ± 3.18 (36) 0.785 0.983
Unpaired T test for normally distributed unpaired data, unpaired Mann–Whitney test for non-normally distributed unpaired data, and Fisher’s test for binary
distributed unpaired data. The p values were corrected for false discovery rate (FDR).
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agreement with the outcome of a comprehensive meta-analysis
showing that PD patients on ropinirole did not have a higher risk
of constipation compared to placebo, while those on pramipexole
had a higher risk of constipation18. Unlike the Wexner score, the
Rome III (constipation and defecation) score did not change over
time in PD patients, which may be explained by the fact that
Rome III assesses symptoms retrospectively over a 3-month period
and may reduce sensitivity to change. The difference observed
between the two questionnaires confirms the need to develop
more sophisticated protocols to detect and investigate GI
symptoms in PD patients8.
Notably, only entacapone exposure in rapid progressing PD
patients contributed to fecal tdc-abundance. Enterococcus (genus
consisting of species harboring TDCs) among others were found to
be significantly increased only in PD patients treated with
entacapone6. However, in their study, Weis et al. did not report
whether the tested PD patients were on medications such as MAOi
or DA agonists, other than levodopa and/or entacapone6. Here we
show that, in addition to entacapone, other anti-PD medications
seem to affect gut bacterial tdc-gene abundance (Table 3).
The major limitation of this study is that we determined
bacterial tdc-gene abundance in fecal samples, which may not be
reflective of actual tdc-gene levels in the small intestine, the main
absorption site of levodopa and other medications. Moreover, the
presence of these genes does not necessarily reflect TDC activity.
In summary, the present study implies important associations
between anti-PD medication and gut bacterial tdc-gene abun-
dance. These associations point toward complex interactions
between anti-PD medication, GI symptoms, and gut bacterial tdc-
gene abundance, which warrants further research.
METHODS
Cohort
The original age and sex-matched cohort was recruited for a pilot study in
2015 investigating PD and gut microbiota5. All subjects were invited to a
follow-up on average 2.25 ± 0.20 years later to investigate temporal
stability in the PD microbiota4. The study was approved by the ethics
committee of the Hospital District of Helsinki and Uusimaa. All participants
gave written informed consent and the study was registered at
clinicaltrials.gov (NCT01536769).
Of the total 165 subjects (77 PD, 88 HCs) recruited at baseline and
follow-up4,5, 13 subjects (6 PD, 7 HC) were excluded because they did not
return for the follow-up study and 20 subjects (4 PD, 16 HCs) were
excluded because of various other reasons at baseline or follow-up. In the
control group, 1 subject was excluded for a sibling with PD, 3 subjects for
having a common cold, 8 subjects for hyposmia (pre-motor PD symptom),
2 subjects for recent surgery, 1 subject had no matching sample, and
1 sample was missing. In the PD group, 1 subject was excluded because of
recent surgery, 1 subject had a change in diagnosis, 1 subject because of a
sampling handling issue, and 1 subject because of medical history. In total,
33 subjects (10 PD, 23 HCs) were excluded, resulting in 132 subjects (67 PD,
65 HCs) in this study.
The following parameters were assessed as described in the previous
studies Scheperjans et al.5 and Aho et al.4: GI symptoms (Wexner
constipation score19, Rome III questionnaire20), disease severity (UPDRS21),
and medication exposure.
DNA extraction
Stool sample collection and DNA isolation were performed in a previous
study4. Briefly, stool samples were collected by study subjects into
collection tubes pre-filled with DNA stabilizer (PSP Spin Stool DNA Plus Kit,
STRATEC Molecular) and stored in the refrigerator until transport (for up to
3 days). After receipt of samples, they were transferred to −80 °C. DNA
from both baseline and follow-up samples were extracted with the PSP
Spin Stool DNA Plus Kit (STRATEC Molecular). Each extraction batch
included one blank sample to assess potential contamination. (Of note, to
prevent potential technical differences, DNA from baseline samples were
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Determination of tdc-gene abundance
DNA concentration of samples was directly estimated from 96-well plates by
measuring the (pathlength corrected) absorbance at 260 and 320 nm in a
multimode reader. The DNA concentration was calculated as follows: 50 ×
(sample260–320− blank260–320). Samples that were negative, very low, or very
high in concentration were measured with the nanodrop to confirm. All DNA
samples were diluted 20× so that the concentration would fall within the
range of 2–25 ng/µl (median, 13.7 ng/µl, interquartile range, 6.9 – 21.8 ng/µl)
and 2 µl was used for quantitative PCR (qPCR). qPCR of tdc genes was
performed using primers Dec5f (5’-CGTTGTTGGTGTTGTTGGCACNACNGAR
GARG-3’) and Dec3r (5’-CCGCCAGCAGAATATGGAAYRTANCCCAT-3’), targeting
a 350 bp region of the tdc gene22. For primers targeting 16S rRNA gene for
all bacteria23, Eub338 (5’-ACTCCTACGGGAGGCAGCAG-3’) and Eub518
(5’-ATTACCGCGGCTGCTGG-3’) were used as internal controls for sample bias
and total bacterial load. All qPCR experiments were performed in a Bio-Rad
CFX96 RT-PCR system (Bio-Rad Laboratories, Veenendaal, The Netherlands)
with iQ SYBR Green Supermix (170–8882, Bio-Rad) in 10 μl reactions using the
manufacturer’s protocol. qPCR was performed using the following parameters:
3min at 95 °C; 15 s at 95 °C, 1min at 58 °C, 40 cycles. A melting curve was
determined at the end of each run to verify the specificity of the PCR
amplicons. Data analysis was performed using the Bio-Rad CFX Manager
3.1 software. Ct[DEC] values were corrected for sample bias and total bacterial
load with the internal control (Ct[16 s]) and linearized using 2^−(Ct[DEC]−
Ct[16s]) based on the 2^−ΔΔCt method24.
Statistics
All statistical tests were performed in IBM SPSS Statistics version 26. The
p value adjustments were performed in R version 4.0.0 using p.adjust
(p-values, “fdr”). The qPCR data were tested for outliers per group and time
point using the ROUT method (Q= 0.1%) in GraphPad Prism v7 and
the identified outliers were removed. Outlier removal was restricted to
the qPCR data only. All variables were tested for normality using
Kolmogorov–Smirnov and Shapiro–Wilk tests using the Explore function
in SPSS. Based on the distribution of data, the differences were tested
using the appropriate statistical tests. The group sizes and appropriate
statistical tests are indicated in the tables. GLMs were performed using the
Generalized Linear Models function in SPSS and the main effects were
tested using Wald Chi Square test. Additionally, the VIF was computed to
check for potential collinearity between variables.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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